Sagent Pharmaceuticals, Inc. has launched Atracurium Besylate Injection, USP, the generic form of the neuromuscular blocker Tracrium, in 50 mg per 5 mL latex-free vials.

According to IMS data for the twelve-months ended March 2012, the US market for Atracurium approximated $2.4 million. As with all products in Sagent's portfolio, Atracurium features the company's PreventIV MeasuresSM packaging and labeling designed to aid in the reduction of medication errors.

“Atracurium is currently on the FDA and ASHP shortage lists with very limited availability,” said Jeffrey M Yordon, president, CEO and chairman of the Board of Sagent. “We are pleased to offer customers a source of this important anaesthetic product and help to alleviate another product shortage.”

Atracurium Besylate Injection is a nondepolarizing skeletal muscle relaxant. It is indicated as an adjunct to general anaesthesia, to facilitate endotracheal intubation and to provide skeletal muscle relaxation during surgery or mechanical ventilation.

Sagent Pharmaceuticals Inc., is a specialty pharmaceutical company focused on developing, manufacturing, sourcing and marketing pharmaceutical products, with a specific emphasis on injectable products.